Indonesia's Best Hospital Margins, Half the Price

Mitra Keluarga Karyasehat (MIKA.JK) posted the highest EBITDA margin, a measure of how much of every sales dollar survives as cash profit, of any hospital operator on the Indonesian stock exchange in 2025. Not the biggest. Not the fastest-growing bed count. The most profitable, by a wide margin, on every dollar of revenue it books.

The stock trades at roughly half the earnings multiple of its closest domestic competitor.

Here's the part that should make you sit up: the company told investors, in its own presentation, that patient volumes declined in the first half of 2025. Revenue grew anyway. That's not a typo and it's not a rounding trick. It's a company that got more profitable by seeing fewer patients, and the market is pricing that as a warning sign rather than a strength. Whether it's right to do that is the whole question this piece tries to answer.

The Numbers That Matter

Start with what's undeniable. For fiscal year 2025, Mitra Keluarga reported revenue of IDR 5,368.3 billion, up 10.1% year over year. Net income came in at IDR 1,364.8 billion, up 19.1%: profit grew almost twice as fast as sales.

Net margin expanded to 25.42%, from 23.52% the year before. Return on equity, net income divided by shareholder equity, a measure of how efficiently a company turns its own capital into profit, sits at 17.98% on a trailing basis. Both numbers are moving the right direction, not just sitting at a high level.

The balance sheet backs it up. Debt to equity is effectively zero. The current ratio, a liquidity measure comparing short-term assets to short-term liabilities, has stayed above 4x for five straight years: more than four dollars of near-term assets for every dollar of near-term liabilities owed. Free cash flow has been positive every single year, including 2025, its heaviest capital-spending year on record. Capex ran 18.2% of revenue and the company still generated IDR 959.5 billion in free cash flow.

This is not a leveraged growth story propped up by debt or an accounting trick. It's a hospital company that funds its own expansion out of its own cash and still throws off surplus.

Where the Growth Actually Came From

Here's the uncomfortable half of the story, and it's uncomfortable because the company disclosed it itself, not because an analyst dug it up.

In the first half of 2025, Mitra Keluarga's revenue grew 4.5% year over year "despite patient volume decline," in the company's own words, from its own investor presentation. Patients showed up less. Revenue went up anyway. How?

Payor mix. Private-pay patients, people paying cash or through private insurance rather than through the government scheme, went from 84.9% of revenue in the first half of 2024 to 87.8% in the first half of 2025. Meanwhile revenue from JKN (Jaminan Kesehatan Nasional, Indonesia's national health insurance program, run day to day through the agency BPJS Kesehatan, so this piece uses "JKN" and "BPJS" for the same government scheme, the way "Social Security" and "SSA" both point at the same US program) fell 15.1% in absolute terms.

Why does that swing profits so hard? JKN reimburses hospitals through INA-CBG, a bundled-tariff system: Indonesia's version of a diagnosis-related-group payment model, where the government pays one fixed fee per case type, regardless of how many days the patient stays or what a la carte services get delivered. Multiple studies of specific procedures, cesarean sections among them, find that INA-CBG tariffs often sit below the actual unit cost of delivering that care, especially at private "Type B" hospitals, the mid-tier rung of Indonesia's hospital classification system (Type A hospitals are the top referral centers with the widest specialist bench, Type D the most basic) where most of Mitra Keluarga's network sits.

Every BPJS patient a hospital treats can run at breakeven or worse under that tariff structure. Every private-pay patient in the same bed runs at a real margin. So Mitra Keluarga is quietly filtering its patient mix toward the profitable segment and getting paid handsomely for it.

The uncomfortable question is what happens once that filtering process runs its course. You can't shift payor mix by three percentage points a year forever. JKN exposure is already down to 12.2% of first-half 2025 revenue. At some point the lever runs out of travel, and the company needs actual patient growth to keep growing earnings. Nobody, including the company, has said what happens then.

Revenue grew 4.5% in the first half of 2025 "despite patient volume decline," by the company's own account. That's the whole thesis in one sentence.

Best Margins, Third-Biggest Footprint

Put Mitra Keluarga next to the three other IDX-listed hospital operators and the margin gap is stark.

Operator	EBITDA margin	Hospitals
Mitra Keluarga (MIKA)	37.88%	31
Siloam (SILO)	29.1%	~41-45
Hermina (HEAL)	24.77%	~42
Sarana Meditama / EMC (SAME)	18.65%	fewer, smaller

Siloam and Hermina both run larger hospital networks than Mitra Keluarga. Hermina, by one industry estimate, has meaningfully more beds too (roughly 6,200 versus Mitra Keluarga's 4,160, though treat that gap as approximate: bed-count reporting across Indonesian hospital groups is inconsistent). Neither scale advantage shows up in their profitability. Mitra Keluarga runs a smaller network more profitably than either of its bigger domestic rivals.

That's the case for calling this a genuinely well-run business rather than a company simply riding a favorable payor mix. Operating discipline shows up in the margin line: procurement leverage from running two focused brands, the premium Mitra Keluarga flagship (21 hospitals) and the mid-tier Kasih Group (10 hospitals), plus a full-time-specialist doctor model rather than the visiting-doctor arrangement common elsewhere in Indonesia.

The honest counterpoint: none of that amounts to a moat that keeps Siloam or Hermina out. Both are comparably or more scaled by hospital count and bed count. Nothing in the evidence points to patient-side switching costs or network effects protecting Mitra Keluarga specifically. Licensing is a real barrier to entry for the industry as a whole (Indonesia's private hospital market is worth USD 21.8 billion in 2025, and the country runs just 1.38 hospital beds per 1,000 people, badly underpenetrated next to regional peers), but that barrier protects incumbents generally, not Mitra Keluarga against these two rivals specifically.

The Discount, and Why It's Not Free Money

Mitra Keluarga trades at roughly 17.7-17.9x trailing earnings and 10.9x EV/EBITDA (enterprise value to EBITDA, a valuation measure that adjusts for cash and debt). Siloam trades at roughly 36.5x earnings and 14.3x EV/EBITDA, about double Mitra Keluarga on the earnings multiple. Malaysia-listed regional peer IHH Healthcare trades around 32-36x earnings. On every conventional multiple, Mitra Keluarga is the cheapest quality hospital operator in the region.

The stock is down about 35% from its 52-week high, from IDR 2,710 to a current price around IDR 1,760.

That's a real discount on a real business. It is not, however, a risk-free one. Our own three-scenario forward model, extrapolating from trailing earnings growth against a range of price-to-earnings exit multiples over a three-year horizon, produces a bull case of +92.7%, a base case of +28.7%, and a bear case of -20.3%. The bear case still implies the stock falls further from today's already-discounted price.

A bear case that still implies further downside is not a margin of safety. It is the market's own uncertainty, priced into the stock.

Governance: Clean at the Top, Opaque One Layer Down

Mitra Keluarga is controlled by the Setiawan family, who also control Kalbe Farma (KLBF), Indonesia's largest listed pharmaceutical company. In 2026 the two companies confirmed an oncology tie-up. No related-party transaction value has been disclosed for that arrangement, so there's no way, from public information, to judge whether the terms favor one company's shareholders over the other's. That gap is compounded by a stale oversight bench: no new independent commissioner has been appointed at Mitra Keluarga since 2020.

The operating side looks healthier. President Director Rustiyan Oen has run day-to-day operations since 1997, and held the top executive role since 2014. He isn't a Setiawan family member, and he stayed in place through founder Dr. Boenjamin Setiawan's death in 2023, a reasonably clean separation between family ownership and operating control that matters more for a hospital network than for most businesses: continuity in a specialist-dependent operation is not a nice-to-have.

The Regulatory Ground Is Shifting Under the Whole Industry

Indonesia's Omnibus Health Law, with implementing regulations that took effect in 2026, raised the foreign ownership cap on hospitals from 67-70% up to 100%, and cut the minimum bed requirement for a specialty hospital from 200 down to 100. Both changes lower the bar for new entrants, including foreign-backed ones, into the same urban Java markets where Mitra Keluarga operates. This doesn't hit Mitra Keluarga specifically; it hits the whole industry's barrier to entry, including the one moat pillar, licensing, that was doing real work.

Separately, a national shortage of roughly 35,337 specialist doctors is a genuine constraint on Mitra Keluarga's own growth plans: roughly 1,400 new beds across 8 sites, funded entirely out of internal cash flow with no debt. You can build the buildings. Staffing them with full-time specialists, the model that gives Mitra Keluarga its margin edge in the first place, is a harder problem the whole country is short-handed on solving.

Two policy trends cut the other way, in Mitra Keluarga's favor specifically. KRIS, a reform that collapses BPJS's old Class 1/2/3 inpatient room tiers, the different-priced accommodation levels hospitals used to sell government-insured patients, into one standardized service level, pressures JKN-tier pricing more for the BPJS-heavy operators (Hermina, Siloam) than for Mitra Keluarga, given how low and falling its JKN exposure already is. And Indonesia's Health Ministry has begun explicitly urging affluent citizens to shift from BPJS to private insurance, a policy direction, not yet a completed reform, that points straight at the segment Mitra Keluarga has already been chasing.

One more data point on the ceiling above all four listed operators: Indonesia loses an estimated USD 9-10 billion a year to medical tourism outflow, mostly to Singapore, Malaysia, and Thailand. Even Mitra Keluarga's premium domestic positioning hasn't closed the credibility gap with the top of the regional market, a ceiling on the bull case that has nothing to do with anything Mitra Keluarga's management can control.

What Actually Belongs in Your Model

Skip two numbers you may have seen elsewhere. A "95% doctor retention rate" and a "USD 900 billion Indonesian digital health market" figure both circulate in commentary about this stock. Neither holds up (the market-size figure is literally larger than Indonesia's entire GDP), and neither belongs here.

What does belong: a debt-free hospital operator with the best margins in its listed peer group. A real, disclosed patient-volume problem that management is currently offsetting rather than solving. A valuation gap to domestic and regional peers that's real, but not a guaranteed floor, the bear case still loses money from here. A governance structure that's clean at the operating level and opaque at the related-party level. And a regulatory environment handing the industry easier entry with one hand while handing Mitra Keluarga specifically a friendlier reimbursement mix with the other.

That combination doesn't sort neatly into "cheap stock, buy it" or "value trap, avoid it." It sorts into something less satisfying and more honest: a fundamentally sound business that hasn't yet proven it can grow without leaning on a payor-mix trick with a limited runway left in it.

Watch, don't chase. The single number that resolves the ambiguity is patient volume in FY2026. If Mitra Keluarga returns to actual volume growth on top of its already-favorable payor mix, the discount to Siloam looks like a mispricing waiting to close. If volumes keep declining while the payor-mix shift runs out of room at the same time, the earnings growth justifying today's multiple stalls, and the "cheap relative to peers" framing stops mattering. Size any position for that uncertainty, not around it.